1 / 6

Multiple Myeloma Therapeutics in Major Developed Emerging Supplementary Treatments Markets to 2021

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10-15 years, and have improved median survival rates by about 50%

john2222deere
Download Presentation

Multiple Myeloma Therapeutics in Major Developed Emerging Supplementary Treatments Markets to 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multiple Myeloma Therapeutics in Major Developed Markets to 2021 By RnRMarketResearch.com Publisher Name : GBI Research Date: 01-Jul-2015 No. of pages: 119 Single User License: US $4995 Browse more Reports on cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Multiple Myeloma Therapeutics in Major Developed Markets to 2021 Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10-15 years, and have improved median survival rates by about 50%. The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Multiple Myeloma Therapeutics in Major Developed Markets to 2021 ProductsDiscussed/Mentioned in this Research: Thalomid (thalidomide) - Celgene, Revlimid (lenalidomide), Pomalyst (pomalidomide), Velcade (bortezomib), Kyprolis (carfilzomib), Farydak (panobinostat) and Chemotherapy - Doxil (doxorubicin HCl liposome injection) Explore More Research Report on Cancer Therapeutics Market. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Multiple Myeloma Therapeutics in Major Developed Markets to 2021 Scope For Multiple Myeloma Therapeutics in Major Developed Markets to 2021 • The MM market landscape has undergone significant change over the past two decades. • Which classes of drug have emerged to dominate the market? • What survival benefits have these drugs produced? • How do the leading marketed therapies compare clinically? • The pipeline contains a range of molecule types and molecular targets not present in the current market, including a strong focus on therapies targeting common oncogenic pathways, such as the Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/Akt) pathway. • Which molecular targets appear most frequently in the pipeline? • How will the new therapies be positioned in the treatment of MM? • How have selected late-stage pipeline therapies performed in clinical trials? • MM clinical trials have an overall attrition rate of 78%. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Multiple Myeloma Therapeutics in Major Developed Markets to 2021 Reasons to Buy: • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in MM. • Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies and a heatmap directly comparing safety and efficacy data. • Analyzethe MM pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast. • Predict growth in market size in eight major markets, with in-depth market forecasting from 2014-2021. The forecasts will provide an understanding of how epidemiology trends, new drug entry, and patent expirations will influence market value. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Multiple Myeloma Therapeutics in Major Developed Markets to 2021 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related